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Endo(cannabinoids) are considered to possess immunomodulatory properties 
and may be involved in airway pathophysiology. In human bronchial epithelial 
(16HBE14o-) cells we reported that the endocannabinoid virodhamine known 
to act as a non-selective agonist on the two cannabinoid (CB) receptors 
modulates the cellular level of cAMP and Ca2+, both of which might control cell 
survival. Here we report that virodhamine reduced 16HBE14o- cell survival, 
apparently largely independent of CB receptor driven cAMP and Ca2+ 
alterations. To dissect CB1R and CB2R functions in 16HBE14o- cells, we 
suppressed cellular CB1R or CB2R expression by transient transfection of 
specific siRNAs. Protein levels of CB1R and CB2R were substantially reduced 
in these cells as assessed by using specific antibodies, whereas expression 
of β-actin was not altered. Silencing of CB1R enhanced virodhamine-induced 
reduction in cell survival, whereas silencing of CB2R had the opposite effect. 
Similar changes were observed with regard to the phosphorylation of the 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) in CB receptor 
silenced 16HBE14o- cells. In conclusion, our data indicate that CB1R and 
CB2R regulate virodhamine induced attenuation of 16HBE14o- cell survival in 








In the past decade two cannabinoid receptors, CB1R and CB2R, have been 
identified, cloned, expressed and functionally investigated (Matsuda et al., 
1990; Munro et al., 1993). The CB receptors together with their endogenous 
lipid ligands are referred to as the endocannabinoid system (Mackie, 2006; 
Pacher et al., 2006; Pertwee, 2006). Currently, the endocannabinoid system 
has been implicated both in the central and peripheral nervous system as well 
as in peripheral organs in many physiological and pathophysiological 
processes, including metabolic regulation, craving, pain, anxiety, bone growth, 
and immune function (Mackie, 2006; Pacher et al., 2006; Pertwee, 2006). 
Such signaling diversity is reflected by CB receptor expression profiles, the 
CB1R being expressed not only in central and peripheral nervous structures 
(Tsou et al., 1998) but also in some peripheral tissues (Liu et al., 2002; 
Wagner et al., 2001), whereas the CB2R is mainly expressed in immune cells 
(Berdyshev, 2000; Galiegue et al., 1995; Munro et al., 1993; Schatz et al., 
1997).  
As members of the G-protein-coupled receptor superfamily both CB1R and 
CB2R couple to heterotrimeric G proteins of the pertussis toxin (PTX)-
sensitive Gi/o family, however coupling to Gs proteins has been reported for 
the CB1R as well (Demuth and Molleman, 2006; Howlett et al., 2002; 
Matsuda et al., 1990; Munro et al., 1993). In most tissues and cells, inhibition 
of cAMP formation by CB receptor coupling to Gi proteins has been shown in 
most tissues and cells, (Howlett et al., 2002). In addition, inhibition of voltage-
operated Ca2+ channels and activation of inwardly-rectifying K+ channels upon 
stimulation of CB1Rs has been reported (Mackie, 2006); however, opposing 
effects of the endocannabinoid system on intracellular Ca2+ have also been 
revealed (Oz, 2006).  
CB receptor signaling properties comprise not only modulation of adenylyl 
cyclase and ion channels but also phosphorylation and activation of members 
of the mitogen-activated protein (MAP) kinase family, such as the extracellular 
signal-regulated kinases 1 and 2 (ERK1/2), p38 MAP kinase and c-Jun N-
terminal kinase (Demuth and Molleman, 2006; Howlett et al., 2002). 
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Modulation of MAP kinase signaling may contribute to the control of cell 
survival by the endocannabinoid system (Guzman et al., 2002).  
In chapter 4 we showed that human bronchial epithelial cells (16HBE14o-) 
endogenously express both CB1R and CB2R which were functionally coupled 
to adenylyl cyclase (Gkoumassi et al., 2007). Using the endocannabinoid 
virodhamine we demonstrated that CB2R activation inhibits cAMP formation 
and interleukin-8 (IL-8) release from 16HBE14o- cells. Pre-treatment with PTX 
unmasked stimulation of cAMP formation, a process involving the CB1R. The 
endocannabinoid virodhamine also profoundly altered cellular Ca2+ handling 
in 16HBE14o- cells by inducing, in particular at concentrations above 10-30 
μM, a clear cellular Ca2+ overload (chapter 4). As it is generally believed that 
regulation of cellular Ca2+, either acting alone or in concert with cAMP, is of 
major importance to control cell survival, in particular under conditions of 
cellular Ca2+ overload (Mayr and Montminy, 2001; Orrenius et al., 2003), the 
aim of the present study was to analyze whether and, if so, by which 
mechanisms cell survival of 16HBE14o- cells is modulated by the 
endocannabinoid virodhamine. Here we report for the first time that 
virodhamine alters cell survival of 16HBE14o- cells. Surprisingly, this cellular 
response was largely independent of CB receptor induced alterations in cAMP 
and Ca2+. Following silencing of CB1R and CB2R using siRNAs, we found that 
CB1R silencing enhanced virodhamine-induced reduction of cell survival, 
whereas CB2R silencing had the opposite effect. Importantly, alterations of 
cell survival in CBR silenced 16HBE14o- cells were accompanied by changes 
on cellular ERK1/2 responses. 
 
Materials and Methods 
 
Chemicals and drugs - All compounds were of analytical grade and obtained 
from Sigma (Zwijndrecht, The Netherlands), unless stated otherwise. 
Virodhamine [O-(2-Aminoethyl)-5Z,8Z,11Z,14Z-eicosatetraenoate] was 
obtained from Tocris-Cookson (Avonmouth, UK). Stock solutions of 
virodhamine and pertussis toxin were prepared in ethanol, shielded from light 
and stored at -20°C. Trypsin was obtained from Lonza (Belgium). The anti-β-
actin antibody was from Sigma (Zwijndrecht, The Netherlands), the anti-
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phospho-ERK1/2 (P-ERK1/2) and the anti-ERK1/2 (ERK1/2) antibodies were 
from Cell Signaling (via Bioke, Leiden, The Netherlands).  
 
Cell Culture - The immortal human bronchial epithelial cell line 16HBE14o- 
was kindly donated by Dr. D. C. Gruenert, University of Vermont, Burlington 
VT, USA) (Cozens et al., 1994). Cells from passages 70-90 were grown at 
37°C in minimum essential  medium (MEM), supplemented with 10% fetal-
bovine serum from PerbioScience (Etten-Leur, The Netherlands), penicillin 
(50 µg/ml), streptomycin (50 µg/ml) and L-glutamine (2 mM) in 
fibronectin/collagen type 1 (Cohesion Technologies Palo Alto, CA) coated 
flasks to near confluency and in an atmosphere of 5% CO2/ 95% O2. All 
culture media and supplements were obtained from Life Technologies (Breda, 
The Netherlands). Cell culture dishes were from Costar (Badhoevedorp, The 
Netherlands) and flasks from Greiner (Alphen a/d Rijn, The Netherlands). To 
study the role of Gi proteins, 16HBE14o- cells were pretreated with PTX 
essentially as described before. Briefly, PTX was added at a concentration of 
100 ng/ml medium for 20 h, as described also in chapter 4 (Gkoumassi et al., 
2007). 
 
Cell survival protocol - 16HBE14o- cells were washed twice with HEPES 
buffered saline (HBS), trypsinised and subjected to two additional washing 
steps with HBS. 16HBE14o- cells were resuspended in a buffer containing 145 
mM NaCl, 5 mM KCl, 0.5 mM MgSO4, 1 mM CaCl2, 10 mM glucose, 10 mM 
HEPES, pH 7.4, plus 0.2 % (w/v) bovine serum albumine (BSA), centrifuged 
for 5 min at room tempurature (1,000 rpm) and washed twice with the same 
solution. Prior to cell counting the cells were incubated for the indicated 
periods of time at 37°C with the indicated concentrations of virodhamine or its 
solvent ethanol. For cell counting, cell suspensions were mixed with equal 
amounts of trypan blue solution (Fluka) (Berd, 2003). Thereafter, living cells 
and dead cells, together comprising total cells, were counted using a Zeiss 





siRNA transfection - 16HBE14o- cells were passaged 1 day before 
transfection with CB1R and CB2R specific siRNAs and allowed to grow to 
about 50% confluence in MEM with L-glutamine containing serum and 
antibiotics. For transfection of 16HBE14o- cells with siRNAs followed by cAMP 
or Ca2+ measurements, the cells were cultured in T80 culture flasks in 7000 μl 
of the medium mentioned above. In a total volume of 1000 μl EC-R buffer 
(Qiagen), 2 µg of siRNA (final siRNA concentration in the flask, 20 nM) were 
mixed by vortexing, then 12 µl of RNAifect transfection reagent (Qiagen, The 
Netherlands) was added and the final solution was allowed to stand for 15 min 
at room temperature to allow complex formation with siRNA according to the 
manufacturer’s instructions (Qiagen). Thereafter, the siRNA containing 
solution was added to the 16HBE14o- cells and the cells were incubated with 
72 h at 37°C.  
For transfection of 16HBE14o- cells with siRNAs followed by measurements of 
ERK1/2 phosphorylation, the cells were cultured on fibronectin/collagen 
coated 35 mm culture dishes. In a total volume of 1750 μl EC-R buffer, 0.5 µg 
of siRNA (final siRNA concentration on the dish, 20 nM) were mixed by 
vortexing, then 3 µl of RNAifect transfection reagent (Qiagen, The 
Netherlands) was added. The probes were further processed as described 
above. The siRNA for the CB1R was developed against exon 1 of the human 
gene (sense: GCAUGUUUCCCUCUUGUGATT; antisense: 
UCACAAGAGGGAAACAUGCTC) and for the CB2R against exon 2 of the 
human gene (sense: GGAUUAAGGUGUUGACUUGTT; antisense: 
CAAGUCAACACCUUAAUCCTC) (Ambion, the Netherlands), respectively. 
Non-silencing siRNA (Alexa Fluor 488, Qiagen) served as unspecific control 
siRNA. 
 
Intracellular Ca2+ measurements - [Ca2+]i was measured using fura-2 
fluorometry as reported in chapter 2 (Demuth et al., 2005). 16HBE14o- cells 
were trypsinised, cell suspensions were loaded with 3 μM fura-2 
acetoxymethylester at 37°C for 45 min in the dark. Thereafter, fluorescence 




cAMP measurements - 16HBE14o- cells were trypsinised and suspended at 
106 cells/ml in the following buffer containing: 118 mM NaCl, 4.7 mM KCl, 3 
mM CaCl2, 1.2 mM MgSO4, 0.5 mM EDTA, 10 mM glucose, 20 mM HEPES, 
1.2 mM KH2PO4, pH 7.4, including 100 µM 3-Isobutyl-1-methylxanthine 3-
Isobutyl-1-methyl-2,6(1H,3H)-purinedione (IBMX) to prevent cAMP 
degradation, and plated in 24 well plates (2x105 cells per well). The 
experiment was started by adding the indicated concentration of virodhamine 
10 min prior to addition of 0.1 µM forskolin for 10 min. After stopping the 
reaction with perchloric acid (3.5 %) the amount of cAMP produced was 
measured as described previously, using a competitive [3H]cAMP radioligand 
binding assay, as also described in chapter 4 (Gkoumassi et al., 2007). 
 
ERK activation assay - For measurement of ERK activation, 16HBE14o- cells 
were serum-starved overnight and then incubated for 300 sec at 37°C with the 
indicated agents, followed by cell lysis in a buffer containing 1% SDS and 10 
mM Tris/HCl, pH 7.4, and 5 passages through a 25-gauge needle (Keiper et 
al., 2004). Thereafter, the lysates were cleared by centrifugation, followed by 
determination of protein concentration (BCA protein assay kit, Pierce, The 
Netherlands) and incubation in Laemmli buffer for 10 min at 95°C. After SDS-
PAGE and transfer to nitrocellulose membranes, phosphorylated ERK1 and 
ERK2 were detected with the anti-P-ERK1/2 antibody. Densitometric analysis 
of the bands (P-ERK1/2) was performed with Totallab tm (Nonlineair 
Dynamics, Newcastle, U.K.). 
 
Immunoblot Analysis - Cell lysate (corresponding to 10-15 µg protein per lane) 
was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 
using 10% gel at 100V. Proteins in the gel were transferred onto nitrocellulose 
membranes which were subsequently blocked with blocking buffer (Tris-HCl 
50 mM, NaCl 150 mM, Tween-20 0.1%, dried milk powder 5%) for 90 
minutes. Membranes were incubated overnight at 4oC using either polyclonal 
rabbit anti-CB1R (1:1000) or polyclonal rabbit anti-CB2R (1:500), respectively, 
as described in chapter 4 (Gkoumassi et al., 2007). Antibodies were kindly 
provided by Dr. K. Mackie, University of Washington, Seattle WA 98195, USA.  
In addition, membranes were incubated overnight at 4oC using either 
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polyclonal rabbit anti-β-actin (1:2000) or anti-P-ERK1/2 (1:500), respectively 
(Keiper et al., 2004). After washes of 10 minutes each, membranes were 
incubated with horseradish peroxidase-labelled secondary antibodies (1:3000 
in blocking buffer) for 90 minutes at room temperature, followed by another 3 
washes. Antibodies were visualized by enhanced chemiluminescence. Before 
incubation with polyclonal rabbit anti-ERK1/2 (1:500), membranes were kept 
overnight at 4 oC in Tris-HCl 50 mM, NaCl 150 mM, Tween-20 0.1% (w/v) and 
washed three times. The membranes were then incubated with 10 ml of 
RestoreTM Western blot stripping buffer (Pierce, the Netherlands) for 60 
minutes at  37 oC followed by another 4 washes 15 minutes each. 
Subsequently followed by visualization from the antibodies through enhanced 
chemiluminescence. 
 
Data Analysis - Values are expressed as mean values ± s.e. mean. Data were 
analyzed, curves drawn and fitted using SigmaPlot 10 (SYSTAT Software 
Inc., Chicago, USA). Comparison of pairs of treatments was made using 




In chapter 4, we reported that 16HBE14o- cells endogenously express both 
CB1R and CB2R and that activation by the endocannabinoid virodhamine 
induces cellular cAMP and Ca2+ alterations (Gkoumassi et al., 2007). As 
shown in Figures 1 and 5, virodhamine modulates 16HBE14o- cell survival in 
a concentration-dependent fashion reaching its maximum of about 50 % 
inhibition at 100 μM virodhamine. Reduction of cell survival induced by 
virodhamine increased over time (Figure 1A versus Figure 1B). After 300 sec 
the reduction amounted to about 40 %, whereas after 600 sec a reduction of 


























































Figure 1. Attenuation of 16HBE14o- cell survival by virodhamine. 16HBE14o- cells were 
stimulated without (basal) or with the indicated concentrations of virodhamine for 300 sec (A) 
and for 600 sec (B). Thereafter, 16HBE14o- cell survival was determined as described in 












Figure 2. Effect of PTX on virodhamine induced attenuation of 16HBE14o- cell survival. 
16HBE14o- cells were pretreated with 100 ng/ml PTX for 20h. Thereafter, 16HBE14o- cell 
survival was measured without (basal) or with the indicated concentrations of virodhamine for 
300 sec (A) and for 600 sec (B) as described in “Materials and Methods“. Data are presented 
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To study whether virodhamine-induced attenuation of 16HBE14o-cell survival 
involves CB receptor coupling to Gi/o proteins the cells were pretreated for 20 
h with 100 ng/ml of PTX. However, cell pretreatment with PTX did not 
profoundly change virodhamine induced attenuation of cell survival (Figure 1 
versus Figure 2). As we demonstrated in chapter 4, Gi/o protein coupling to 
CB2Rs inhibits cAMP production in 16HBE14o- cells and cell pretreatment 
with PTX unmasked Gs-mediated stimulation of cAMP formation by CB1Rs 
(Gkoumassi et al., 2007), CB receptor driven cAMP alterations seem to be 
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Figure 3. Silencing of CB1R and CB2R expression by CB receptor specific siRNA in 
16HBE14o- cells. 16HBE14o- cells were transfected with unspecific siRNA (sham) or with the 
CB receptor specific siRNAs, as indicated. After 72 h, 16HBE14o- cell lysates were lysed and 
probed as described in “Materials and Methods“. Immunoblot detection of CB1R (A), CB2R (B) 
and β-actin (A and B) in lysates of control cells (sham) and CB receptor specific siRNA 
transfected 16HBE14o- cells. Blots shown are representative of 3-5 experiments. 
 
Although CB1R and CB2R selective antagonists, SR141716A and SR144528 
respectively, either in the presence or absence of PTX, reversed the 
modulatory effects of virodhamine on cAMP accumulation in 16HBE14o- cells 
(Gkoumassi et al., 2007), these compounds did not reduce virodhamine 
induced Ca2+ alterations (chapter 4). To decipher the involvement of individual 
CB receptors on the above mentioned cellular response, in particular to study 
whether CB receptor driven Ca2+ responses alter virodhamine induced 
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reduction of 16HBE14o- cell survival, their endogenous expression was 
suppressed by specific siRNAs. As shown in Figure 3, such maneuver 
diminished cellular expression of CB1R and CB2R leaving the expression of β-
actin unaffected. Silencing of CB1R and CB2R only slightly reduced (10-20%) 
virodhamine-induced Ca2+ alterations in 16HBE14o- cells (Figure 4). Silencing 
of CB2R (and CB1R) also slightly altered virodhamine induced inhibition of 
cAMP production (not shown). Most importantly, however, in the presence of 
virodhamine concentrations above 10 μM, able to reduce of 16HBE14o- cell 
survival (see above), no difference between sham and silenced CB1R and 
CB2R became evident (Figure 4). Taken together virodhamine induced 
reduction of 16HBE14o- cell survival also seems to be largely independent of 
CB receptor mediated Ca2+ alterations. 
 
Intriguingly, silencing of CB receptor expression differentially altered 
virodhamine induced attenuation of 16HBE14o- cell survival. As shown in 
Figure 5, silencing of CB1R expression strongly enhanced 100 μM 
virodhamine induced reduction of cell survival, resulting in almost complete 
inhibition of cell survival. At lower virodhamine concentrations, however, no 
differences with control cells were observed independent of the time interval 
being studied. In contrast, silencing of CB2R expression diminished the impact 
of virodhamine on 16HBE14o- cell survival (Figure 5). In the presence of 100 
μM virodhamine inhibition of 16HBE14o- cell survival amounted to 
approximately 20 % and to 30 % after 300 sec and 600 sec, respectively, in 









Figure 4. Effect of CB receptor silencing on virodhamine induced intracellular Ca2+ alterations 
in 16HBE14o- cells. 16HBE14o- cells were transfected with unspecific siRNA (sham) or with 
the CB receptor specific siRNAs as indicated. After 72 h, the cells were stimulated with 10 μM 
virodhamine (A), 20 μM virodhamine (B) or 30 μM virodhamine (C) each added at t=60 sec. 
Representative traces (left panels) and  mean values ± s.e.mean from 4 experiments (right 
panels) are depicted. 
30 µM Virodhamine
Time (sec)





































































































































Figure 5. Effect of CB receptor silencing on virodhamine induced attenuation of 16HBE14o- 
cell survival. 16HBE14o- cells were transfected with unspecific siRNA (sham) or with the CB 
receptor specific siRNAs as indicated. After 72 h, the cells were stimulated without (basal) or 
with the indicated concentrations of virodhamine for 300 sec (A) or 600 sec (B) followed by 
cell survival measurements as described in “Materials and Methods“. Data are presented as 
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Figure 6. Effect of CB receptor silencing 
on ERK1/2 responses in 16HBE14o- 
cells. 16HBE14o- cells were transfected 
with unspecific siRNA (Sham) or with the 
CB receptor specific siRNAs as indicated. 
After 72 h, the cells were stimulated 
without (Basal) or with 3 μM ATP, 30 μM 
virodhamine and the indicated 
combination (Both). Phosphorylation of 
ERK1/2 (P-ERK1/2) and the total cellular 
content of ERK1/2 were detected in cell 
lysates with an anti-phospho-ERK1/2 and 
an anti-ERK antibody, respectively.  Blots 








As it is now generally accepted that control of cell survival by the 
endocannabinoid system involves members of the MAP kinase family 
(Guzman et al., 2002), we studied ERK1/2 responses in 16HBE14o- cells as 
well. Previous unpublished studies from our laboratory had revealed that 
16HBE14o- cells respond to purine nucleotides by elevating [Ca2+]i (not 
shown). As purinergic receptors are now believed to control cell survival via 
ERK1/2 as well (Ahmad et al., 2006), activation of ERK1/2 by ATP was used 
as control for the present virodhamine experiments. Virodhamine by itself did 
not phosphorylate ERK1/2 (Figure 6A). 
 
Stimulation of 16HBE14o- cells with ATP strongly increased ERK1/2 
phosphorylation, an effect being completely blocked in the presence of 
virodhamine (Figure 6A). As illustrated in Figures 6B and 6C, silencing of CB 
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receptors reciprocally changed ERK1/2 responses in 16HBE14o- cells. In 
CB1R silenced cells stimuli induced phosphorylation of ERK1/2 was 
completely abolished (Figure 6B). In contrast, CB2R silencing unmasked a 
stimulatory component of virodhamine on ERK1/2 phosphorylation, which was 
not dramatically altered in the presence of ATP (Figure 6C). CB receptor 
silencing did not alter expression of ERK1/2 in 16HBE14o- cells. Effects of 
CB1R and CB2R silencing on cellular ERK1/2 phosphorylation matched the 




Here we report for the first time that the endocannabinoid virodhamine, known 
to act on both CB1R and CB2R being endogenously expressed in 16HBE14o- 
cells, as we discussed in chapter 4 (Gkoumassi et al., 2007), profoundly 
affects cell survival. Virodhamine reduced 16HBE14o- cell survival in a 
concentration- and time-dependent manner. Worthwhile to note is that the 
virodhamine concentration being required to attenuate 16HBE14o- cell 
survival was about 100 times higher than the concentration being used to 
inhibit cellular cAMP accumulation and interleukin-8 release (chapter 4) 
(Gkoumassi et al., 2007). Such difference might explain the ineffectiveness of 
PTX (Figures 1 and 2), known to efficiently alter cAMP formation in 
16HBE14o- cells (Gkoumassi et al., 2007), to alter virodhamine-induced 
attenuation of cell survival. Both CB1R and CB2R are differentially coupled to 
adenylyl cyclase, hence, it is rather unlikely that these signaling properties are 
of major importance for virodhamine-induced attenuation of 16HBE14o- cell 
survival. 
As reported before and also shown in this paper, virodhamine induced at 
concentrations above 10 μM Ca2+ overload in 16HBE14o- cells (see Figure 4). 
Remarkably, such virodhamine concentrations (Figures 1 and 5) 
concentration- and time-dependently reduced 16HBE14o- cell survival 
implying that virodhamine induced cellular Ca2+ overload might be responsible 
for its effect on cell survival. Such mechanism would perfectly fit to numerous 
reports in the literature indicating that Ca2+ ions modulate cell survival 
(Orrenius et al., 2003). Therefore we aimed to unravel the impact of Ca2+ 
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overload induced by virodhamine on 16HBE14o- cell survival and in particular 
to gain insight into the potential involvement of CB1R and CB2R in such 
scenario. Although CB1R and CB2R antagonists, SR141716A and SR144528 
respectively, as shown in chapter 4, selectively altered cAMP responses in 
16HBE14o- cells (Gkoumassi et al., 2007), these compounds failed to 
antagonise virodhamine induced Ca2+ alterations. Based on these findings we 
decided to interfere on the level of CB1R and CB2R expression using the 
siRNA technology (Dykhoorn et al., 2003). 
To our knowledge this is the first report on silencing of CB1R and CB2R in 
16HBE14o- cells and its impact on virodhamine induced cellular responses. 
The CB1R and CB2R specific siRNA sequences being used in the present 
study were rather specific as expression of β-actin was not changed in CB 
receptor silenced cells; in addition, expression of CB1R vs. CB2R remained 
unchanged in CB2R vs. CB1R silenced cells, respectively (not shown). 
Silencing of CB1R and CB2R, however, did not dramatically alter virodhamine 
induced Ca2+ responses and the same was true with inhibition of cAMP 
formation (not shown); most strikingly there was no difference between CB1R 
and CB2R silencing (Figure 4). The second messengers cAMP and Ca2+ are 
importantly involved in the control of cell fate (Beavo and Brunton, 2002; 
Berridge et al., 2004), it would be rather unlikely that virodhamine induced 
attenuation of 16HBE14o- cell survival is independent of cAMP and Ca2+; 
however, based on the findings reported here would suggest that CB receptor 
induced cAMP and Ca2+ alterations are less relevant. 
 
Strikingly, silencing of CB1R and CB2R exerted opposing effects on 
virodhamine induced attenuation of 16HBE14o- cell survival. These findings 
further emphasize the CB receptor specificity of the siRNAs being used in the 
present study. Whereas silencing of CB1R induced a further reduction of cell 
survival, silencing of CB2R had the opposite effect (Figure 5). As silencing of 
CB1R and CB2R had similar reciprocal effects on ERK1/2 phosphorylation in 
16HBE14o- cells (Figure 6), it is tempting to speculate that virodhamine 
induced attenuation of cell survival involve ERK1/2. Indeed members of the 
MAP kinase family like ERK1/2 seem to control cellular fate by 
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endocannabinoids (Guzman et al., 2002). Although ERK signaling has initially 
been reported to positively control cell survival, recent findings indicate that 
ERK signaling might also reduce cell survival; such distinct signaling 
properties seem to involve various scaffold proteins and inhibitors (Kolch, 

















Figure 7. Hypothetical scheme of virodhamine induced attenuation of 16HBE14o- cell survival 
by CB receptors. Virodhamine modulates 16HBE14o- cell survival largely independent of 
cAMP and Ca2+ alterations. Silencing of CBB1R increased virodhamine-induced reduction of 
cell survival, whereas silencing of CB2R had the opposite effect. Silencing of CB receptors 
altered cellular ERK1/2 responses in similar fashions. Whereas CB1R signaling seems to 
enhance cell survival, CB2R signaling diminishes 16HBE14o  cell survival; both effects 
probably involve ERK1/2. 
-
 
(Endo)cannabinoids acting through the CB1R and/or the CB2R have also been 
reported to enhance or to reduce cell survival in various cell types, and these 
processes seemed to involve cAMP and Ca2+ signals. (Davis et al., 2003; 
Ellert-Miklaszewska et al., 2005; Galve-Roperh et al., 2002; Giuliano et al., 
2006; Hsu et al., 2007; Melck et al., 1999; Rueda et al., 2002; Sanchez et al., 
2003; Zhao et al., 2005). However, the same reports indicated, using 
phospho-specific antibodies, that (endo)cannabinoids activate ERK1/2 and/or 
p38 MAP kinase as well. We report here that virodhamine by itself did not 
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induce ERK1/2 phosphorylation in 16HBE14o- cells, but rather dimished 
cellular ERK1/2 phosphorylation. Importantly, however, modulation of cellular 
CB1R and CB2R dramatically altered ERK1/2 responses. In particular, in 
CB2R silenced 16HBE14o- cells virodhamine substantially phosphorylated 
ERK1/2, whereas in CB1R silenced cells phosphorylation of ERK1/2 was 
completely blunted. In line with the findings described in chapter 4 
(Gkoumassi et al., 2007), the CB2R seems to be superior to the CB1R to 
control ERK1/2 responses in 16HBE14o- cells. That ERK1/2 responses in 
16HBE14o- cells are tightly controlled by the cannabinoid system. 
As depicted in the scheme (Figure 7), CB2R signaling might convey a signal 
leading to ERK1/2 inhibition, whereas the opposite scenario seems to account 
for CB1R signaling. The nature of such signals is presently unknown, however 
it is tempting to speculate that members of the β-arrestin family might be 
involved. Although being initially characterized as regulators of G-protein-
coupled receptor desensitization and internalization, recent evidence indicate 
that β-arrestins bear signaling properties independently of G protein activation 
(De Wire et al., 2007). It is now accepted that β-arrestins, in particular β-
arrestin2, function as multiprotein scaffolds for an increasing amount of 
signaling molecules including ERK1/2 (De Wire et al., 2007; Kolch, 2005). As 
CB receptors seem to associate with β-arrestin2, lipid rafts and adaptor 
proteins (Bari et al., 2005; Jin et al., 1999; Sanchez et al., 2001), such 
mechanisms might contribute to the impact of the CB1R and CB2R on ERK1/2 
responses in 16HBE14o- cells, regulating cell survival by the endocannabinoid 
virodhamine. 
 
In conclusion, we report here on regulation of 16HBE14o- cell survival by the 
endocannabinoid virodhamine being apparently largely independent of CB 
receptor dependent cAMP and Ca2+ alterations. The findings reported here 
also indicate that the CB1Rs and CB2Rs reciprocally regulate virodhamine-
induced attenuation of 16HBE14o- cell survival, and such effects probably 
converge on the level of ERK1/2. 
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